Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Identifying priority outcomes that influence selection of disease-modifying therapies in MS.

Day GS, Rae-Grant A, Armstrong MJ, Pringsheim T, Cofield SS, Marrie RA.

Neurol Clin Pract. 2018 Jun;8(3):179-185. doi: 10.1212/CPJ.0000000000000449.

PMID:
30105155
2.

A novel method to combine assessment of benefit and harm: OMERACT 3x3 methodology applied to two active comparator trials.

Boers M, Singh JA, Cofield SS, Bridges SL Jr, Moreland LW, O'Dell JR, Wu H, Leatherman S, Curtis JR.

Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23590. [Epub ahead of print]

PMID:
29691998
3.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324
4.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
5.

Shared Decision Making and Autonomy Among US Participants with Multiple Sclerosis in the NARCOMS Registry.

Cofield SS, Thomas N, Tyry T, Fox RJ, Salter A.

Int J MS Care. 2017 Nov-Dec;19(6):303-312. doi: 10.7224/1537-2073.2016-091.

6.

Diet quality is associated with disability and symptom severity in multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox R, Marrie RA.

Neurology. 2018 Jan 2;90(1):e1-e11. doi: 10.1212/WNL.0000000000004768. Epub 2017 Dec 6.

PMID:
29212827
7.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

8.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

9.

Regulation of autophagy, mitochondrial dynamics, and cellular bioenergetics by 4-hydroxynonenal in primary neurons.

Dodson M, Wani WY, Redmann M, Benavides GA, Johnson MS, Ouyang X, Cofield SS, Mitra K, Darley-Usmar V, Zhang J.

Autophagy. 2017;13(11):1828-1840. doi: 10.1080/15548627.2017.1356948. Epub 2017 Sep 29.

10.

O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease.

Wani WY, Ouyang X, Benavides GA, Redmann M, Cofield SS, Shacka JJ, Chatham JC, Darley-Usmar V, Zhang J.

Mol Brain. 2017 Jul 19;10(1):32. doi: 10.1186/s13041-017-0311-1.

11.

Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis.

Marrie RA, Cutter GR, Tyry T, Cofield SS, Fox R, Salter A.

Mult Scler Relat Disord. 2017 Apr;13:87-92. doi: 10.1016/j.msard.2017.02.013. Epub 2017 Feb 20.

PMID:
28427709
12.
13.

Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.

Wang G, Cutter GR, Cofield SS, Lublin F, Wolinsky JS, Gustafson T, Krieger S, Salter A.

Mult Scler. 2017 Jun;23(7):982-987. doi: 10.1177/1352458516670733. Epub 2016 Sep 28.

14.

Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.

Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S Jr, Reddy ST.

Arthritis Rheumatol. 2017 Jan;69(1):46-57. doi: 10.1002/art.39833.

15.

Health insurance affects the use of disease-modifying therapy in multiple sclerosis.

Wang G, Marrie RA, Salter AR, Fox R, Cofield SS, Tyry T, Cutter GR.

Neurology. 2016 Jul 26;87(4):365-74. doi: 10.1212/WNL.0000000000002887. Epub 2016 Jun 29.

16.

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.

Ormseth MJ, Yancey PG, Solus JF, Bridges SL Jr, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Kon V, Michael Stein C; TETRAD Investigators.

Arthritis Rheumatol. 2016 Sep;68(9):2099-105. doi: 10.1002/art.39675.

17.

Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.

Liu Y, Morgan C, Hornung L, Tyry T, Salter AR, Agashivala N, Belletti DA, Kim E, Fox RJ, Cofield SS, Cutter GR.

J Neurol Sci. 2016 Mar 15;362:121-6. doi: 10.1016/j.jns.2016.01.034. Epub 2016 Jan 19.

PMID:
26944131
18.

Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.

Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon JM, Paulus H, Bridges SL Jr, Curtis JR.

Arthritis Rheumatol. 2016 Mar;68(3):577-86. doi: 10.1002/art.39502.

19.

Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.

Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila MI, Cofield SS, Shadick N, Nigrovic PA, St Clair EW, Bingham CO 3rd, Furie R, Robinson W, Genovese M, Striebich CC, O'Dell JR, Thiele GM, Moreland LW, Levesque M, Bridges SL Jr, Gregersen PK, Niewold TB.

Ann Rheum Dis. 2016 Oct;75(10):1757-62. doi: 10.1136/annrheumdis-2015-208001. Epub 2015 Nov 6.

20.

The Relationship Between HIV Risk, High-Risk Behavior, Religiosity, and Spirituality Among Black Men Who Have Sex with Men (MSM): An Exploratory Study.

Watkins TL Jr, Simpson C, Cofield SS, Davies S, Kohler C, Usdan S.

J Relig Health. 2016 Apr;55(2):535-48. doi: 10.1007/s10943-015-0142-2.

PMID:
26475314
21.

The Relationship of Religiosity, Spirituality, Substance Abuse, and Depression Among Black Men Who Have Sex with Men (MSM).

Watkins TL Jr, Simpson C, Cofield SS, Davies S, Kohler C, Usdan S.

J Relig Health. 2016 Feb;55(1):255-68. doi: 10.1007/s10943-015-0101-y.

PMID:
26286843
22.

Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study.

Govindarajan KA, Datta S, Hasan KM, Choi S, Rahbar MH, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group.

Hum Brain Mapp. 2015 Oct;36(10):3749-3760. doi: 10.1002/hbm.22875. Epub 2015 Jun 19.

23.

Impact of multiple sclerosis relapse: The NARCOMS participant perspective.

Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA.

Mult Scler Relat Disord. 2015 May;4(3):234-40. doi: 10.1016/j.msard.2015.03.005. Epub 2015 Mar 27.

24.

Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.

Datta S, Staewen TD, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group.

Mult Scler Relat Disord. 2015 Mar;4(2):124-36. doi: 10.1016/j.msard.2015.01.004. Epub 2015 Jan 17.

25.

Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.

Ranganath VK, Motamedi K, Haavardsholm EA, Maranian P, Elashoff D, McQueen F, Duffy EL, Bathon JM, Curtis JR, Chen W, Moreland L, Louie J, Amjadi S, O'Dell J, Cofield SS, St Clair EW, Bridges SL Jr, Paulus HE.

Arthritis Care Res (Hoboken). 2015 Jul;67(7):929-39. doi: 10.1002/acr.22541.

26.

Body Mass Index Is Associated With Mucosal Disease in Crohn's: Results of a Case-Control Study.

Malik TA, Kaslow RA, Cofield SS, Mannon PJ.

Gastroenterology Res. 2014 Dec;7(5-6):111-117. Epub 2014 Dec 27.

27.

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry.

Salter AR, Marrie RA, Agashivala N, Belletti DA, Kim E, Cutter GR, Cofield SS, Tyry T.

Patient Prefer Adherence. 2014 Jul 4;8:971-9. doi: 10.2147/PPA.S49903. eCollection 2014.

28.

Recruitment of participants to a multiple sclerosis trial: the CombiRx experience.

Bhanushali MJ, Gustafson T, Powell S, Conwit RA, Wolinsky JS, Cutter GR, Lublin FD, Cofield SS.

Clin Trials. 2014 Apr;11(2):159-66. doi: 10.1177/1740774513517184.

29.

Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.

O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL Jr, Ranganath VK, Moreland LW; TEAR Trial Investigators.

Arthritis Rheum. 2013 Aug;65(8):1985-94. doi: 10.1002/art.38012.

30.

Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.

Curtis JR, McVie T, Mikuls TR, Reynolds RJ, Navarro-Millán I, O'Dell J, Moreland LW, Bridges SL Jr, Ranganath VK, Cofield SS.

J Rheumatol. 2013 May;40(5):572-8. doi: 10.3899/jrheum.120715. Epub 2013 Apr 15.

31.

Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR.

Arthritis Rheum. 2013 Jun;65(6):1430-8. doi: 10.1002/art.37916.

32.

Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS; CombiRx Investigators.

Ann Neurol. 2013 Mar;73(3):327-40. doi: 10.1002/ana.23863. Epub 2013 Mar 11.

33.

The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics.

Lindsey J, Scott T, Lynch S, Cofield S, Nelson F, Conwit R, Gustafson T, Cutter G, Wolinsky J, Lublin F; the CombiRx Investigators Group.

Mult Scler Relat Disord. 2012 Apr 1;1(2):81-86. Epub 2012 Feb 23.

34.

Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.

Maska LB, Sayles HR, O'Dell JR, Curtis JR, Bridges SL Jr, Moreland LW, Cofield SS, Mikuls TR.

Arthritis Care Res (Hoboken). 2012 Dec;64(12):1804-10. doi: 10.1002/acr.21758.

35.

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS; TEAR Investigators.

Arthritis Rheum. 2012 Sep;64(9):2824-35. doi: 10.1002/art.34498.

36.

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, Gustafson T, Cutter GR, Wolinsky JS, Lublin FD; CombiRx Investigators Group.

Mult Scler Relat Disord. 2012 Apr;1(2):81-6. doi: 10.1016/j.msard.2012.01.006. Epub 2012 Feb 23.

PMID:
25876935
37.

Refractory hypertension: definition, prevalence, and patient characteristics.

Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA.

J Clin Hypertens (Greenwich). 2012 Jan;14(1):7-12. doi: 10.1111/j.1751-7176.2011.00556.x. Epub 2011 Nov 15.

38.

Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study.

Narayana PA, Govindarajan KA, Goel P, Datta S, Lincoln JA, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS; MRI Analysis Center at Houston; The CombiRx Investigators Group.

Neuroimage Clin. 2012 Nov 30;2:120-31. doi: 10.1016/j.nicl.2012.11.009. eCollection 2012.

39.

Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals?

Kaiser KA, Cofield SS, Fontaine KR, Glasser SP, Thabane L, Chu R, Ambrale S, Dwary AD, Kumar A, Nayyar G, Affuso O, Beasley M, Allison DB.

Int J Obes (Lond). 2012 Jul;36(7):977-81. doi: 10.1038/ijo.2011.207. Epub 2011 Nov 8. Review.

40.

Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.

Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA.

J Hum Hypertens. 2012 Aug;26(8):502-6. doi: 10.1038/jhh.2011.60. Epub 2011 Jun 16.

41.

Hospice use in Alabama, 2002-2005.

Jenkins TM, Chapman KL, Ritchie CS, Arnett DK, McGwin G, Cofield SS, Maetz HM.

J Pain Symptom Manage. 2011 Feb;41(2):374-82. doi: 10.1016/j.jpainsymman.2010.04.027. Epub 2011 Jan 13.

PMID:
21236629
42.

Use of causal language in observational studies of obesity and nutrition.

Cofield SS, Corona RV, Allison DB.

Obes Facts. 2010 Dec;3(6):353-6. doi: 10.1159/000322940. Epub 2010 Dec 10.

43.

Recruitment and retention of patients into emergency medicine clinical trials.

Cofield SS, Conwit R, Barsan W, Quinn J.

Acad Emerg Med. 2010 Oct;17(10):1104-12. doi: 10.1111/j.1553-2712.2010.00866.x. Review.

44.

Assessing changes in relapse rates in multiple sclerosis.

Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, Cutter GR.

Mult Scler. 2010 Dec;16(12):1414-21. doi: 10.1177/1352458510379246. Epub 2010 Sep 1. Review.

PMID:
20810517
45.

Barriers to hospice care in Alabama: provider-based perceptions.

Jenkins TM, Chapman KL, Ritchie CS, Arnett DK, McGwin G Jr, Cofield SS, Maetz HM.

Am J Hosp Palliat Care. 2011 May;28(3):153-60. doi: 10.1177/1049909110380199. Epub 2010 Aug 27.

PMID:
20801920
46.

Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.

Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA.

J Clin Sleep Med. 2010 Aug 15;6(4):363-8.

47.

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA.

J Hum Hypertens. 2010 Aug;24(8):532-7. doi: 10.1038/jhh.2009.96. Epub 2009 Dec 17.

48.

Assessment of risk tolerance for adverse events in emergency department chest pain patients: a pilot study.

Brown TB, Cofield SS, Iyer A, Lai R, Milteer H, Queen B, Schwab MH, Menchine M, Schriger DL.

J Emerg Med. 2010 Aug;39(2):247-52. doi: 10.1016/j.jemermed.2009.03.026. Epub 2009 May 5.

PMID:
19406604
49.

Instructions to "push as hard as you can" improve average chest compression depth in dispatcher-assisted cardiopulmonary resuscitation.

Mirza M, Brown TB, Saini D, Pepper TL, Nandigam HK, Kaza N, Cofield SS.

Resuscitation. 2008 Oct;79(1):97-102. doi: 10.1016/j.resuscitation.2008.05.012. Epub 2008 Jul 17.

50.

Aldosterone excess and resistance to 24-h blood pressure control.

Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA.

J Hypertens. 2007 Oct;25(10):2131-7.

PMID:
17885558

Supplemental Content

Loading ...
Support Center